PARIS, France, SEPTEMBER 6, 2023 at 6 p.m. (CET) – Pharnext SCA (FR001400GUN7 – ALPHA)
(the “Company”), a biopharmaceutical company at an advanced clinical stage developing new therapies for neurodegenerative diseases with no satisfactory therapeutic solution, presents the number of shares and voting rights making up the share capital, in accordance with the provisions of article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
|
Date |
Number of shares making up the capital |
Number of GROSS voting rights |
Number of NET voting rights |
08/31/2023 | 3,909,336,626 | 3,909,336,626 | 3,909,336,626 |
Furthermore, the company recalls that, since 1
er
January 2023, the number of shares issued each month by the company breaks down as follows:
|
Wording |
OCEANE CONVERSION |
BSA EXERCISE | ||
Number of OCEANE converted | Number of shares created | Number of warrants | Number of shares created | |
|
Before consolidation | ||||
January 2023 | 200 | 240 010 495 | 20,302,608 | 20,302,608 |
February 2023 | 68 | 578 132 700 | 20,177,456 | 20,177,456 |
March 2023 | 150 | 5,447,619,045 | 442 838 613 | 442 838 613 |
April 2023 | 0 | 0 | 33,774,890 | 33,774,890 |
|
After grouping | ||||
May 2023 | 82 | 1,712,176 | 554 621 | 554 621 |
June 2023 | 200 | 38,474,975 | 8,434,524 | 8,434,524 |
July 2023 | 100 | 430 508 248 | 66,537,465 | 66,537,465 |
August 2023 | 48 | 3,221,422,857 | 143,009,795 | 143,009,795 |
The number of shares newly issued for conversions as well as the total number of shares in circulation are kept on the Company’s website: HERE
About Pharnext
Pharnext is a late-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases that currently have no satisfactory therapeutic solution. Pharnext has a new drug candidate, PXT3003, in development for Charcot-Marie-Tooth disease type 1A (CMT1A), an inherited, rare and debilitating peripheral neuropathy. PXT3003 has orphan drug status in Europe and the United States. In 2018, PXT3003 completed a Phase III clinical study, the PLEO-CMT trial, with encouraging preliminary results. This trial was followed by an open-label extension study, the PLEO-CMT-FU trial, in which 120 patients are still currently continuing treatment with PXT3003. The long-term results suggest a sustained benefit, in terms of tolerance and efficacy, after a total clinical study period of 5 years. A pivotal international Phase III clinical study, the PREMIER trial, is ongoing, in which 387 patients with CMT1A have been enrolled. The first results of the PREMIER trial are expected in the fourth quarter of 2023. PXT3003 was discovered with the R&D approach of Pleotherapy™. Pharnext draws investors’ attention to the risk factors, particularly financial, detailed in its financial reports. More information on www.pharnext.com.
Pharnext is listed on the Euronext Growth market in Paris (ISIN code: FR001400GUN7).
contacts
|
Financial Press Relations NEWS finance & communication Anne-Charlotte Dudicourt [email protected] +33 (0)1 53 67 36 32 |
Investor Relations NEWS finance & communication Jerome Fabreguettes Leib [email protected] +33 (0)1 53 67 36 78 |
[1]
Consolidation by way of exchange of 10,000 old shares for 1 new share
This post has the “? Actusnews SECURITY MASTER” service.
– SECURITY MASTER Key:
nGltlJtplG3ImHGdlMqWbpJlm2lklpPFbGOZyJOZaZucaG9imZuUbJ2YZnFim2ln
– To check this key:
https://www.security-master-key.com.
Regulated information:
Total number of voting rights and capital:
– Information relating to the total number of voting rights and shares making up the capital
Full and original press release in PDF format:
https://www.actusnews.com/news/81641-pharnext_ddv_20230831.pdf
© Copyright Actusnews Wire
Receive the company’s next press releases free of charge by email by subscribing to www.actusnews.com